QPPV.COM KNOWLEDGE ASSESSMENT

ICSR Management for Biological Medicinal Products

Test your understanding of the concepts covered by ICSR Management for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A reporter describes urticaria and breathing difficulty treated as anaphylaxis but does not clearly state that a diagnosis of anaphylaxis was made. What is the best coding approach?

Always code confirmed anaphylaxis because it is the most clinically serious term Code the supported signs and symptoms, preserve the verbatim description, and use a definitive diagnosis only when supported Code only 'adverse event' because symptoms cannot be coded Replace the reporter's description with the company's preferred diagnosis

Question 2 of 10 Which interpretation best describes biological plausibility in causality assessment?

It proves that the medicine caused the event It indicates consistency with known pharmacology, immunology, or product characteristics and supports, but does not establish, a causal hypothesis It replaces the need to consider alternative explanations It is determined solely by the presence of a batch number

Question 3 of 10 Two reports describe the same patient and event, but one names the active substance and the other names a brand. How should duplicate assessment proceed?

Treat them as different cases because the product names differ Treat them as duplicates automatically because any reports concerning the same active substance are duplicates Compare clinical, temporal, reporter, product, batch, device, and reference details and document a reasoned manual determination Delete the less detailed report without preserving its information

Question 4 of 10 Why is recording only the international non-proprietary name often insufficient for a biological ICSR?

The active substance is never relevant to biological-product assessment Several products sharing an active substance may differ in brand, formulation, device, batch, or manufacturing context The INN is prohibited from being transmitted in an ICSR The INN can only be used for concomitant medicines

Question 5 of 10 What does technical acceptance of an E2B(R3) message by a gateway demonstrate?

That the clinical facts are true and causality is correct That the message has been technically received or passed specified validation, not that the medical content is accurate That the batch defect has been confirmed That all required follow-up has been completed

Question 6 of 10 A homecare provider receives a valid report three days before it is transferred to the marketing authorisation holder's central safety database. Which date generally controls the start of the regulatory reporting clock?

The date the central safety database creates the case The date the case is medically reviewed The date the covered organisation or partner first received the minimum information for a valid report The date the reporter confirms the batch number

Question 7 of 10 Which statement correctly distinguishes seriousness from severity?

Seriousness and severity are interchangeable regulatory terms A severe event is always serious, while a mild event is never serious Seriousness concerns regulatory outcomes or consequences, whereas severity describes intensity Seriousness is determined only by the product's reference safety information

Question 8 of 10 Why can improvement after stopping a long-acting biological be difficult to interpret as a dechallenge?

Long-acting products cannot cause adverse reactions after administration The product may continue to exert pharmacological or pharmacodynamic effects after discontinuation Dechallenge is relevant only to chemically synthesised medicines Improvement after discontinuation always proves causality

Question 9 of 10 A patient who previously responded to a biological develops worsening disease after an injection device failed to deliver the full dose. Which interpretation is most appropriate?

The event is necessarily secondary loss of response caused by anti-drug antibodies The event is necessarily a batch defect Incomplete delivery is a plausible administration or device contributor, but disease activity and other causes should still be assessed Loss of response cannot be reported when a device is involved

Question 10 of 10 A patient switches from a reference biological product to a biosimilar and develops symptoms after the third biosimilar dose. Which conclusion is most scientifically appropriate at intake?

The switch proves that the biosimilar caused the event The event should be attributed to the entire biological class without further assessment The switching sequence is an important exposure fact and hypothesis, but causality and attribution remain to be assessed The biosimilar should not be recorded because biosimilars are interchangeable for all safety purposes

ICSR Management for Biological Medicinal Products

Cookie Settings